NEW YORK, July 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Bristol-Myers Squibb Co (NYSE: BMY), Abbott Laboratories (NYSE: ABT), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Mallinckrodt PLC (NYSE: MNK) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4519-100free.
Bristol-Myers Squibb Co Analyst Notes
On July 1, 2014, Bristol-Myers Squibb Co (Bristol-Myers Squibb) reported that it will release its Q2 2014 financial results on July 24, 2014. A conference call hosted by Company executives to discuss the results will follow at 10:30 a.m. EDT. Interested parties can listen to the webcast by logging on to Bristol-Myers Squibb's website. The full analyst notes on Bristol-Myers Squibb areavailable to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/BMY/report.pdf
Abbott Laboratories Analyst Notes
On June 25, 2014, Abbott Laboratories (Abbott) announced that it would present in its Q2 2014 financial statements on July 16, 2014, before market opening. A live webcast will follow that same day at 8:00 a.m. CT/9:00 a.m. ET and can be viewed via the Company's website. A replay will also be made available on that day beginning 11:00 a.m. CT. The full analyst notes on Abbott are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/ABT/report.pdf
Alexion Pharmaceuticals, Inc. Analyst Notes
On July 3, 2014, shares of Alexion Pharmaceuticals, Inc. (Alexion) closed at $164.21, reflecting a 0.01% decline over its previous day's close. Over the past five-day trading sessions, the Company's shares gained 2.54%, while the NASDAQ Composite returned 2.44% over the same time period. The stock has a 52-week low of $93.72 and a 52-week high of $185.43. The full analyst notes on Alexion are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/ALXN/report.pdf
Mallinckrodt PLC Analyst Notes
On July 3, 2014, Mallinckrodt PLC's (Mallinckrodt) stock gained 3.30% from its previous day's close to end the trading session at $81.27. Mallinckrodt's stock has gained an upside of 4.82% over the past one month of trade, outperforming the Dow Jones Industrial Average, which returned 2.07% over the same time period. The stock is trading near its 52-week high of $83.03. The full analyst notes on Mallinckrodt are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/MNK/report.pdf
Baxter International Inc. Analyst Notes
On June 26, 2014, Baxter International Inc. (Baxter) issued a press release stating that it would host a conference call to discuss its Q2 2014 financial results on July 17, 2014 at 7:30 a.m. CT. Interested parties may access the call by logging on to Baxter's website. The full analyst notes on Baxter are available to download free of charge at:
http://www.analystsreview.com/Jul-08-2014/BAX/report.pdf
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.AnalystsReview.com
SOURCE Analysts Review
